Can finasteride and tamsulosin be used together to treat benign prostatic hyperplasia in men, and what are the appropriate dosing, safety, and monitoring recommendations?

Combination Therapy with Finasteride and Tamsulosin for BPH

Yes, finasteride and tamsulosin should be used together in men with symptomatic BPH who have enlarged prostates (>30-40 mL) and are at risk for disease progression, as combination therapy provides superior symptom relief and reduces the risk of acute urinary retention and need for surgery compared to monotherapy. 1, 2, 3

Patient Selection for Combination Therapy

The decision to use combination therapy versus monotherapy depends on specific clinical parameters:

Use Combination Therapy When:

• Prostate volume >30-40 mL (documented by ultrasound or DRE)
• Moderate to severe LUTS (IPSS ≥8-12)
• PSA >1.5 ng/mL (suggests larger prostate volume)
• Patient desires to avoid surgery and can commit to long-term therapy

The landmark CombAT study demonstrated that combination therapy with dutasteride and tamsulosin (a 5-ARI/alpha-blocker combination similar to finasteride/tamsulosin) showed statistically significant reductions in clinical progression over 4 years compared to monotherapy 1. The MTOPS trial similarly confirmed that finasteride plus doxazosin reduced disease progression more effectively than either agent alone 2, 3.

Start with Monotherapy When:

• Small prostate volume (<30 mL) → alpha-blocker alone (tamsulosin)
• Mild symptoms (IPSS <8) → consider watchful waiting or alpha-blocker alone
• Rapid symptom relief needed → start tamsulosin first (works within days to weeks)

Dosing Recommendations

Standard Regimen:

• Finasteride: 5 mg once daily 3
• Tamsulosin: 0.4 mg once daily 4
• Both medications taken continuously, typically 30 minutes after the same meal each day (tamsulosin)

Initiation Strategy:

You can start both medications simultaneously or sequentially. Starting tamsulosin first provides rapid symptom relief (1-2 weeks) while finasteride takes 3-6 months to show maximal effect 1, 2. This sequential approach may improve patient adherence by demonstrating early benefit.

Monitoring Protocol

Baseline Assessment:

• IPSS questionnaire score
• Post-void residual (PVR) urine volume
• PSA level (must obtain BEFORE starting finasteride)
• Prostate volume (DRE or ultrasound)
• Sexual function assessment (IIEF or similar)

Follow-up Schedule:

At 3 Months:

• IPSS score
• Assess for adverse effects (sexual dysfunction, orthostatic hypotension, dizziness)
• PVR if initially elevated

At 6-12 Months:

• IPSS score
• PSA (finasteride reduces PSA by ~50%; multiply measured value by 2 for cancer screening) 3
• Prostate volume assessment
• Sexual function reassessment

Annually thereafter:

• IPSS score
• PSA (adjusted for finasteride effect)
• Symptom progression assessment

Safety Considerations and Side Effects

Sexual Dysfunction (Most Common):

The combination increases sexual side effects compared to monotherapy 2, 3:

Finasteride-related (from FDA label): 3

• Decreased libido: 6.4% (vs 3.4% placebo) in year 1
• Erectile dysfunction: 8.1% (vs 3.7% placebo) in year 1
• Decreased ejaculate volume: 3.7% (vs 0.8% placebo)
• Important: Sexual side effects may persist after discontinuation in some patients

Tamsulosin-related: 4

• Abnormal ejaculation: 4.5-7.2%
• Dizziness: 15-17%
• Orthostatic hypotension: 8-17%

Combination therapy: The MTOPS study showed abnormal ejaculation in 14.1% and impotence in 22.6% with combination therapy 2, 3. Research confirms finasteride, not tamsulosin, is primarily responsible for worsening erectile dysfunction and may reduce testosterone levels 5.

Critical Safety Warnings:

Intraoperative Floppy Iris Syndrome (IFIS): Tamsulosin is associated with IFIS during cataract surgery 1. Inform ophthalmologists if patient is taking or has ever taken tamsulosin before any eye surgery.

Prostate Cancer Screening:

• Obtain baseline PSA BEFORE starting finasteride
• Finasteride reduces PSA by approximately 50% after 6 months 3
• Double the PSA value when screening for prostate cancer in men on finasteride
• The PCPT trial showed increased incidence of high-grade (Gleason 8-10) prostate cancer with finasteride (1.8% vs 1.1%), though this remains controversial 3

Cardiovascular Effects: Monitor blood pressure, especially in elderly patients. Tamsulosin can cause significant orthostatic hypotension (17.8% in combination therapy) 2.

Common Pitfalls to Avoid

1. Not obtaining baseline PSA before finasteride: This makes future cancer screening interpretation impossible
2. Forgetting to adjust PSA values: Always multiply PSA by 2 in men taking finasteride for >6 months
3. Starting combination therapy in men with small prostates: Wastes resources and increases side effects without benefit
4. Discontinuing too early: Finasteride requires 6-12 months for maximal prostate volume reduction 1
5. Not counseling about sexual side effects: Patients must understand these risks upfront, as they may be persistent 3, 5
6. Ignoring drug interactions: Tamsulosin with other alpha-blockers or antihypertensives increases hypotension risk

Duration of Therapy

Combination therapy is typically long-term (years). The CombAT study followed patients for 4 years with sustained benefit 1. Discontinuation often leads to symptom recurrence and prostate re-enlargement. If patients cannot tolerate combination therapy, consider:

• Reducing to alpha-blocker monotherapy (loses disease-modifying benefit)
• Switching to 5-ARI monotherapy (slower symptom relief but maintains prostate volume reduction)
• Considering minimally invasive surgical options

Alternative Considerations

While the evidence supports finasteride/tamsulosin, note that dutasteride (dual 5-ARI) may be slightly more effective than finasteride for prostate volume reduction 1, though both are acceptable. The fixed-dose combination of dutasteride/tamsulosin is also available and may improve adherence.

Recent evidence suggests tadalafil 5mg daily plus finasteride may provide comparable urinary symptom relief with better preservation of erectile function compared to tamsulosin/finasteride 6, though this is not yet standard guideline-recommended therapy.